Table 2.

Common VP1 consensus sequences recognized by human PBMCs

Peptide*	VP1 consensus sequence†	Responding donors	SYFPEITHI prediction		Epitope
			Class I score‡	Class II score§
321–333	KEVTQNDGTTTI	16, 19, 50, 51	24	20	A
241–253	TTSTRTWALPTY	16, 50, 51	21	24	B
681–693	EIEWELQKENSK	13, 50, 51	21	26	C
9–21	DWLEDTLSEGIR	16, 50	21	32	D
57–69	NGLDKGEPVNEA	16, 50	20	27	E
113–125	NLGRAVFQAKKR	50, 51	28	20	F
121–133	AKKRVLEPLGLV	40, 50	29	20	G
249–261	LPTYNNHLYKQI	16, 51	24	24	H
257–269	YKQISSQSGASN	16, 51	–	23	I
265–277	GASNDNHYFGYS	16, 51	26	–	J
313–325	FKLFNIQVKEVT	16, 50	–	23	K
329–341	TTTIANNLTSTV	19, 50	22	24	L
393–405	YCLEYFPSQMLR	16, 50	21	28	M
457–469	QSRLQFSQAGAS	13, 16	–	25	N
553–565	DIEKVMITDEEE	13, 50	21	30	O
716–728	TNGVYSEPRPIGTRYLT	16, 51	24	21	P
505–516	ATKYHLNGRDSL	13, 50, 51	21	25	Q

*Peptide number corresponds to amino acid sequence of VP1. The full lists of peptides and sequences are detailed in Supplementary Tables S1 and S2.

†Consensus sequences were derived from the 12-mer overlap between pairs of PBMC-stimulating VP1 peptides with the exception of the overlap between peptides 90 and 91 which was of 17 amino acids. Pairs of peptide were considered positive if both produced an SI value >1 sd above the mean SI.

‡VP1 sequence was analysed using SYFPEITHI prediction for alleles of the HLA-A and HLA-B loci; output sequences were nonamers. Scores represent an arbitrary peptide binding capacity for each peptide.

§VP1 sequence was analysed using SYFPEITHI prediction for alleles of the HLA-DRB locus; output sequences were 15-mers. For both class I and II, the best score obtained is reported. Scores below 20 are not reported.